Investigating the effect of dexpanthenol cream on the prevention of pregnancy stretch marks in first-time pregnant women.

The effect of topical dexpanthenol cream on the prevention of striae in primigravida women: A double-blind randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240809062706N2

Enrollment

100

Registered

2024-10-02

Start date

2024-09-24

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Striae Gravidarum. Striae atrophicae

Interventions

Intervention 1: Intervention Group: Participants in the intervention group will receive a dexpanthenol cream with a 5% concentration, with each tube containing 175 grams of cream. The other ingredient

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: No previous striae on the abdomen Primigravida A live singleton fetus Gestational age of 20-22 weeks (confirmed by ultrasound or last menstrual period) BMI between 19.8-26 No special dietary restrictions Basic literacy No use of other topical treatments on the abdomen Availability of a contact phone number No intention to change residence within the next 6 months.

Exclusion criteria

Exclusion criteria: History of allergic reactions to the study cream Presence of malignancies in the affected area History of surgery in the affected area Presence of underlying conditions such as diabetes, preeclampsia, connective tissue disorders, clotting disorders, or skin diseases

Design outcomes

Primary

Measure	Time frame
Incidence of Striae: occurrence of pregnancy-related striae. Timepoint: After intervention at 36 to 38 weeks of pregnancy. Method of measurement: Davey’s Scale.	—

Secondary

Measure	Time frame
Severity of Striae. Timepoint: After intervention at 36 to 38 weeks of pregnancy. Method of measurement: Assessment of Striae Severity Using Davey’s Scale.;Incidence and Severity of Itching. Timepoint: After intervention at 36 to 38 weeks of pregnancy. Method of measurement: The Kamini scale.;Incidence and Severity of Erythema. Timepoint: After intervention at 36 to 38 weeks of pregnancy. Method of measurement: The Atwal scale.;Adverse Events. Timepoint: Final assessment at 36 to 38 weeks of pregnancy and after the intervention. Method of measurement: By a 5-item questionnaire.	—

Measure

Time frame

Severity of Striae. Timepoint: After intervention at 36 to 38 weeks of pregnancy. Method of measurement: Assessment of Striae Severity Using Davey’s Scale.;Incidence and Severity of Itching. Timepoint: After intervention at 36 to 38 weeks of pregnancy. Method of measurement: The Kamini scale.;Incidence and Severity of Erythema. Timepoint: After intervention at 36 to 38 weeks of pregnancy. Method of measurement: The Atwal scale.;Adverse Events. Timepoint: Final assessment at 36 to 38 weeks of pregnancy and after the intervention. Method of measurement: By a 5-item questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasumeh Razavi

Tabriz University of Medical Sciences

masumehrazavi78@gmail.com+98 41 3447 2966

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026